Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. (Q53368384)
scientific article
Language:
Current Data About Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
(P31) (Q13442814)
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

(P50) (Q3034980)
(P1545) 8
(P1932) D Belpomme
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018

(Q1438399)
(P1545) 14
(P1932) G Mathé
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

(P304) 1136-1145
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

(P407) (Q1860)

(P433) 4
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

(P478) 14
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

(P577) Monday, April 1, 1996
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

(P921) (Q18936)
(P887)

(Q422232)
(P887)

(Q238512)
(P887)

(P1433) (Q400292)
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

(P1476) "Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration." (language: en)
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

(P2093) J L Misset
(P1545) 1
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

M di Palma
(P1545) 2
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

M Delgado
(P1545) 3
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

R Plagne
(P1545) 4
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

P Chollet
(P1545) 5
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

P Fumoleau
(P1545) 6
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

B Le Mevel
(P1545) 7
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

J Guerrin
(P1545) 9
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

P Fargeot
(P1545) 10
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

R Metz
(P1545) 11
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

M Ithzaki
(P1545) 12
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

C Hill
(P1545) 13
(P248)
(P698) 8648368
(P813) Sunday, May 13, 2018
(P854) http://europepmc.org/abstract/MED/8648368

other details
description scientific article

External Links
(P356) 10.1200/JCO.1996.14.4.1136
(P698) 8648368